共 198 条
[1]
Hendriksz CJ(2013)Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA Mol Genet Metab 110 54-64
[2]
Harmatz P(2013)The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects Mol Genet Metab 109 54-61
[3]
Beck M(2013)Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP) J Inherit Metab Dis 36 373-384
[4]
Jones S(2012)Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA J Inherit Metab Dis 36 309-322
[5]
Wood T(2016)Obstructive airway in Morquio A syndrome, the past, the present and the future Mol Genet Metab 117 150-156
[6]
Lachman R(2016)Surgical reconstruction for severe tracheal obstruction in Morquio A syndrome Ann Thorac Surg 102 e329-331
[7]
Gravance CG(2016)Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome Mol Genet Metab 119 131-143
[8]
Orii T(2016)Impact of long-term elosulfase alfa treatment on respiratory function in patients with morquio a syndrome J Inherit Metab Dis 39 839-847
[9]
Tomatsu S(2018)Impact of long-term elosulfase alfa on activities of daily living in patients with morquio a syndrome in an open-label, multi-center, phase 3 extension study Mol Genet Metab 123 127-134
[10]
Harmatz P(2008)The 6-minute walk test: normal values for children of 4–11 years of age Arch Dis Child 93 464-468